Revolution Medicines, Inc. (RVMD)
NASDAQ: RVMD · Real-Time Price · USD
39.40
+0.31 (0.81%)
At close: May 30, 2025, 4:00 PM
38.64
-0.76 (-1.93%)
After-hours: May 30, 2025, 4:02 PM EDT
Revolution Medicines Stock Forecast
Stock Price Forecast
According to 12 professional analysts, the 12-month price target for Revolution Medicines stock ranges from a low of $55 to a high of $82. The average analyst price target of $68.67 forecasts a 74.29% increase in the stock price over the next year.
Price Target: $68.67 (+74.29%)
Analyst Consensus: Strong Buy
Analyst Ratings
The average analyst rating for Revolution Medicines stock is "Strong Buy". This means that analysts believe this stock is likely to perform very well in the near future and significantly outperform the market.
Recommendation Trends
Rating | Dec '24 | Jan '25 | Feb '25 | Mar '25 | Apr '25 | May '25 |
---|---|---|---|---|---|---|
Strong Buy | 7 | 7 | 8 | 8 | 7 | 7 |
Buy | 6 | 6 | 5 | 5 | 5 | 5 |
Hold | 0 | 0 | 0 | 0 | 0 | 0 |
Sell | 0 | 0 | 0 | 0 | 0 | 0 |
Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
Total | 13 | 13 | 13 | 13 | 12 | 12 |
Latest Forecasts
Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
---|---|---|---|---|---|---|---|
HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Maintains $73 → $72 | Strong Buy | Maintains | $73 → $72 | +82.74% | May 14, 2025 |
Oppenheimer | Oppenheimer | Buy Maintains $70 → $75 | Buy | Maintains | $70 → $75 | +90.36% | May 8, 2025 |
Guggenheim | Guggenheim | Strong Buy Maintains $87 → $80 | Strong Buy | Maintains | $87 → $80 | +103.05% | May 8, 2025 |
Needham | Needham | Strong Buy Reiterates $57 | Strong Buy | Reiterates | $57 | +44.67% | May 8, 2025 |
Wedbush | Wedbush | Buy Reiterates $67 | Buy | Reiterates | $67 | +70.05% | Apr 28, 2025 |
Financial Forecast
Revenue This Year
1.38M
Revenue Next Year
4.70M
from 1.38M
Increased by 241.39%
EPS This Year
-4.81
from -3.58
EPS Next Year
-5.18
from -4.81
Historical EPS numbers are GAAP, while forecasted numbers may be non-GAAP.
Revenue Forecast
Revenue | 2025 | 2026 | 2027 | 2028 | 2029 |
---|---|---|---|---|---|
High | 14.2M | 43.6M | 570.7M | ||
Avg | 1.4M | 4.7M | 140.0M | ||
Low | n/a | n/a | n/a |
Revenue Growth
Revenue Growth | 2025 | 2026 | 2027 | 2028 | 2029 |
---|---|---|---|---|---|
High | - | 3,063.0% | 12,039.5% | ||
Avg | - | 241.4% | 2,877.7% | ||
Low | - | - | - |
EPS Forecast
EPS | 2025 | 2026 | 2027 | 2028 | 2029 |
---|---|---|---|---|---|
High | -4.86 | -4.34 | -1.70 | ||
Avg | -4.81 | -5.18 | -4.84 | ||
Low | -4.71 | -5.48 | -5.80 |
EPS Growth
EPS Growth | 2025 | 2026 | 2027 | 2028 | 2029 |
---|---|---|---|---|---|
High | - | - | - | ||
Avg | - | - | - | ||
Low | - | - | - |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.